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Background: Accumulating data support the in-
volvement of the serotonin (5-hydroxytryptamine 
[5-HT]) system in the pathophysiology of chronic 
fatigue syndrome. Neuropharmacologic studies 
point to a hyperactive 5-HT system, and open-label 
treatment studies with 5-HT3 receptor antagonists 
have shown promising results. In this randomized 
controlled clinical trial, the effect of ondansetron, a 
5-HT3 receptor antagonist, was assessed on fatigue 
severity and functional impairment in adult pa-
tients with chronic fatigue syndrome.
Method: A randomized, placebo-controlled, 
double-blind clinical trial was conducted at 
Radboud University Nijmegen Medical Centre, 
The Netherlands. Sixty-seven adult patients who 
fulfilled the US Centers for Disease Control and 
Prevention (CDC) criteria for chronic fatigue 
syndrome and who were free from current psychi-
atric comorbidity participated in the clinical trial. 
Participants received either ondansetron 16 mg per 
day or placebo for 10 weeks. The primary outcome 
variables were fatigue severity (Checklist Individual 
Strength fatigue severity subscale [CIS-fatigue]) 
and functional impairment (Sickness Impact 
Profile-8 [SIP-8]). The effect of ondansetron was 
assessed by analysis of covariance. Data were ana-
lyzed on an intention-to-treat basis. All patients 
were recruited between June 2003 and March 2006.
Results: Thirty-three patients were allocated to 
the ondansetron condition, 34 to the placebo con-
dition. The 2 groups were well matched in terms 
of age, sex, fatigue severity, functional impair-
ment, and CDC symptoms. Analysis of covariance 
showed no significant differences between the  
ondansetron- and placebo-treated groups during 
the 10-week treatment period in fatigue severity 
and functional impairment.
Conclusions: This clinical trial demonstrates  
no benefit of ondansetron compared to placebo  
in the treatment of chronic fatigue syndrome.
Trial Registration: www.trialregister.nl: 
ISRCTN02536681
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Chronic fatigue syndrome is a medically unexplained syndrome, characterized by severe disabling fatigue 
for a period of at least 6 months that has led to considerable 
impairment in daily functioning.1 Various accompanying 
symptoms may be present, such as headache, joint and 
muscle pain, sore throat, and impaired memory and con-
centration. In The Netherlands, a country with 16 million 
inhabitants, there are probably between 30,000 and 40,000 
patients with chronic fatigue syndrome.2 Of the many thera-
peutic interventions that have been undertaken, so far only 
cognitive behavioral therapy and graded exercise therapy 
are of proven effectiveness.3,4
Neuroendocrinologic investigations have tried to eluci-
date the pathophysiology of chronic fatigue syndrome.5 Data 
in the literature support an important role for serotonin 
(5-hydroxytryptamine [5-HT]) in the pathophysiology of 
chronic fatigue syndrome.6–8 Serotonin plays a diverse and 
important role in the regulation of sleep and wakefulness, 
mood regulation, impulse control, memory, and percep-
tion of pain and in behavior that involves a high cognitive 
demand.9 Increased activity or metabolism of the 5-HT sys-
tem have been implicated in the pathophysiology of chronic 
fatigue syndrome.10–13 An increased 5-HT metabolism in 
fatigue is supported by a rise in plasma tryptophan, the 
precursor of 5-HT during and after sustained exercise in 
healthy persons.14–16
Positive results of the use of 5-HT3 inhibitors in the 
treatment of patients with chronic fatigue due to chronic 
hepatitis17,18 or fibromyalgia19,20 are in line with a role of 
serotonin in fatigue and support further research into this 
type of pharmacologic interventions.
Results of an open-label pilot study performed by our 
research group showed positive results during 1-month 
treatment with granisetron, a 5-HT3 receptor antagonist.21 
The results of the pilot study encouraged us to investigate 
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the effect of ondansetron in a well-defined chronic fatigue 
syndrome population using validated outcome measures in 
a randomized, double-blind, placebo-controlled design.
METHOD
The study was approved by the medical ethical commit-
tee of the Radboud University Nijmegen Medical Centre. 
Written informed consent was obtained from all partici-
pants prior to enrollment.
Participants
Patients were recruited through the outpatient clinic 
of the Department of General Internal Medicine of the 
Radboud University Nijmegen Medical Centre. Further-
more, patients with chronic fatigue syndrome who were 
referred by general practitioners to the Nijmegen Expert 
Centre Chronic Fatigue for treatment were also asked to 
participate in the clinical trial.
Patients were eligible for participation if they met 
the following inclusion criteria: aged between 18 and 65 
years, satisfying the 1994 US Centers for Disease Control 
and Prevention (CDC) consensus criteria for chronic fa-
tigue syndrome,1 and scoring above clinical cut-off on the 
Checklist Individual Strength fatigue severity subscale and 
the Sickness Impact Profile-8 (see below).
At the end of 2003, the International Chronic Fatigue 
Syndrome Study Group presented recommendations for 
better application of the 1994 case definition of chronic 
fatigue syndrome.22 The 1994 CDC criteria for defining 
chronic fatigue syndrome have been superseded by the re-
vised 2003 CDC criteria. In our clinical trial, we did not use 
the 2003 CDC criteria because the inclusion of the study 
started before the publication of the revised 2003 CDC cri-
teria. The Structured Clinical Interview for DSM-IV Axis 
I Disorders (SCID-I)23 was performed by the investigator 
with a clinical background, who was trained in the SCID-I 
interview, to exclude patients with current psychiatric co-
morbidity. Pregnant or lactating women were excluded, as 
were patients with lactose intolerance and patients taking 
psychotropic drugs or experimental medications.
Interventions
Ondansetron (8-mg tablets) and an identical placebo 
were delivered by the manufacturer GlaxoSmithKline, The 
Netherlands. There was no difference in taste, appearance, 
or packaging between the active supplements and the pla-
cebo tablets. During 10 weeks, the chronic fatigue syndrome 
patients took either ondansetron (two 8-mg ondansetron 
tablets) or 2 placebo tablets at night. The dose of 16 mg per 
day was based on the results of the pilot study performed 
before this clinical trial.21 In the pilot study, we observed a 
positive treatment effect with an equipotent dose of 16 mg 
ondansetron per day at night, and the patients tolerated the 
medication relatively well.
Späth et al24 reported positive effects in patients with 
chronic fatigue syndrome treated with 16 mg per day, as 
well.
Design and Procedures
The study was a prospective, randomized, double-blind, 
placebo-controlled trial. The study was fully designed by the 
investigators and executed independently of the manufac-
turer of the study drugs.
The outcome measures were assessed before the start of 
the pharmacologic interventions and at the end of the 10-
week treatment period, when the patients were still taking 
the medication. All participants, investigators, and labora-
tory technicians were blinded to the treatment condition.
Randomization
Before the start of the clinical trial, the hospital phar-
macy prepared 70 treatment packages. Randomization and 
allocation to the treatment or placebo group was based on a 
patient’s study number. The pharmacy held the randomiza-
tion list that correlated the study number with the treatment 
group. To maintain balance over time, the concealed ran-
domization was done in blocks of 10. Treatments were 
generated randomly within the blocks using a computer 
program (Excel, Microsoft, Redmond, Washington, http://
www.microsoft.com). After acceptance of a patient by the 
junior researcher (G.K.H.T.) and the clinical psychologist 
(G.B.), the eligible patient received the lowest study number 
available (1–70).
Primary Outcome Measures
Fatigue severity. The Checklist Individual Strength is 
a reliable and validated self-report questionnaire. We used 
the Checklist Individual Strength fatigue severity subscale 
(CIS-fatigue).4,25,26 The score on this 8-item scale ranges 
from 8 (no fatigue) to 56 (maximally fatigued). The cut-off 
point for severe fatigue was set at 35.27 Patients who had 
chronic fatigue syndrome with a fatigue severity score of 
35 or higher were included.
Functional impairment. The Sickness Impact Profile-8 
(SIP-8) measures the influence of symptoms on daily func-
tioning, using the following 8 subscales to rate both physical 
and psychological disability: home management, mobility, 
alertness behavior, sleep/rest, ambulation, social interac-
tions, work, and recreation and pastimes.4 A total score was 
calculated by addition of the weights of items. This widely 
used measure has good reliability and validity.28 Patients 
with chronic fatigue syndrome with substantial functional 
impairments, ie, a score of 800 or higher, were included.
Patients had to fulfill both the fatigue severity and func-
tional impairment criteria to participate in the study.
Secondary Outcome Measures
Activity level. Besides self-reported outcome measures, 
we measured physical activity with an actometer (Medical 
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Instruments Services, Radboud University Nijmegen Medi-
cal Centre, Nijmegen, The Netherlands).29 An actometer is a 
small motion-sensing device that can register and quantify 
human physical activity. The actometer is attached to the 
ankle; it was worn continuously for 12 consecutive days and 
nights during the assessment periods. It consists of a piezo-
electric sensor that is sensitive in 3 directions, and it detects 
movements of the leg (eg, during walking or climbing stairs). 
Accelerations of the sensor above a predefined threshold 
are considered as activity and are stored into an internal 
memory of the actometer. Each second, the counter of the 
actometer is read and reset by the micro controller, which 
adds the value to the integration counter. The integration 
counter is set at 5 minutes, providing every 5 minutes an 
activity score that is stored into the internal memory of the 
actometer. A general physical activity score that expressed 
the mean activity level over the 12 days in the mean number 
of accelerations per 5-minute interval was calculated.30,31
Daily fatigue level. During the 2-week actometer period, 
patients rated their fatigue levels in a diary. They rated their 
levels of fatigue 4 times a day on a 0 (no fatigue) to 4 (maxi-
mally fatigued) scale.
The 4 scores for each day were summed to produce the 
daily observed fatigue (DOF) score, which ranged from 0 to 
16.30 The mean of 12 consecutive DOF scores was used.
Statistical Methods
For all analyses, SPSS 14.0 (SPSS Inc, Chicago, Illinois, 
http://www.spss.com) was used.
Power calculations before the start of the trial showed that 
30 persons were needed in each group to detect a difference 
of at least 1 standard deviation (SD) on the CIS-fatigue with 
a power of 90% and a 2-tailed significance level of 5%. An-
ticipating a dropout rate of 10%, 66 persons needed to be 
recruited. Analyses were performed on an intention-to-treat 
basis.
Missing values were replaced by way of mean imputa-
tion.32 The effect of ondansetron was assessed by analysis 
of covariance (ANCOVA) of the posttreatment scores af-
ter 10 weeks as the dependent variable, the baseline scores 
as covariate, and condition as fixed factor.33 Analyses were 
completed before the code was broken.
RESULTS
All patients were recruited between June 2003 and 
March 2006. Figure 1 illustrates participant flow through 
the trial. In total, 159 patients were given information about 
the study protocol; 79 persons refused to participate, and 
the main reason given for refusal was the intensity of the 
study. Thirteen patients did not meet the inclusion criteria. 
Seventy-four patients were screened with the SCID-I 
Interview. Of those, 7 were excluded due to current psychi-
atric comorbidity. A total of 67 patients, without current 
psychiatric comorbidity, were allocated randomly to the 
ondansetron group or to the placebo group.
The ondansetron (n = 33) and placebo (n = 34) groups 
did not differ with respect to age, gender, fatigue severity, 
impairment, or number of CDC symptoms (Table 1).
During the screening process, we obtained data from all 
the patients who did not want to participate.
There was no significant difference in age, number of 
CDC symptoms, fatigue severity, or functional impairment 
between the patients with chronic fatigue syndrome par-
ticipating in the clinical trial and those who chose not to 
participate (data not shown).
In the placebo arm, no participants dropped out. Three 
patients in the ondansetron arm dropped out within the 
first 2 weeks of the trial. One patient agreed to participate 
in the posttesting assessments, and 2 patients in the on-
dansetron group had missing values for the posttreatment 
measurements. The main reason for discontinuing the trial 
Figure 1. Participant Flow
Abbreviation: CFS = chronic fatigue syndrome.
Assessed for eligibility (N = 159)
Randomization (n = 67)
Refused participation n = 79
Burden of study n = 39
Did not want medication n = 20
Inconvenient timing n = 5
Other CFS treatment n = 5
(Planned) pregnancy n = 4
Did not believe in CFS
 research with ondansetron n = 2
Reason unknown n = 4
Not eligible n = 13
Current psychiatric comorbidity
 Depression n = 5
 Anxiety disorder n = 1
 Obsessive-compulsive disorder n = 1
Current treatment for CFS n = 3
Current treatment for pain n = 2
Age n = 1
Ondansetron
Assigned (n = 33)
Completers (n = 30)
Placebo
Assigned (n = 34)
Completers (n = 34)








Age, y 35.8 (9.9) 34.7 (9.4) … .64
Sex, female 67 74 … .54b
CIS-fatigue 49.4 (6.3) 50.0 (4.7) 0.424 .67c
SIP-8 1,375 (470) 1,359 (593.4) 0.117 .907c
CDC symptoms 7.4 (1.4) 6.8 (2.1) 1.34 .183c
aValues are means (SD) except for sex, which is given as percentage 
female.
bChi-square test.
cIndependent sample t test.
Abbreviations: CDC = US Centers for Disease Control and Prevention, 
CIS-fatigue = Checklist Individual Strength fatigue severity subscale, 
SIP-8 = Sickness Impact Profile-8.
Ondansetron RCT in Chronic Fatigue Syndrome
J Clin Psychiatry 71:5, May 2010 531
was an increased general feeling of malaise. Ondansetron 
and placebo treatments were relatively well tolerated. Four 
patients (3 ondansetron and 1 placebo) had complaints of 
constipation, and a laxative syrup was prescribed. No other 
important side effects were reported in either group.
Primary Outcomes
Evaluation of fatigue severity and functional impairment 
posttreatment scores showed no significant differences 
between the ondansetron and placebo groups. The posttreat-
ment scores of both groups remained in the clinical range of 
severe fatigue and substantial functional impairment.
Our primary analysis was to impute the missing values 
of the 2 patients using mean imputation.
Moreover, we performed a sensitivity analysis testing 2 
imputation methods: first by imputing the last observation 
carried forward and second by imputing the maximum 
score (worst case scenario) of the primary outcome mea-
sures. Both imputating methods had no significant impact 
on the conclusions of the primary analysis.
Secondary Outcomes
Posttreatment actometer activity scores and DOF scores 
of the ondansetron and placebo group did not differ sig-
nificantly. F-statistics and mean scores of the primary and 
secondary outcomes are shown in Table 2.
DISCUSSION
This randomized, double-blind, controlled clinical 
trial investigated the therapeutic potential of the sero-
tonin receptor antagonist ondansetron. We did not find 
significant differences between the ondansetron- and placebo- 
treated groups during the 10-week treatment period for 
any dimension of chronic fatigue syndrome. This result 
was rather unexpected given the promising results in an 
earlier open study in which we tested the effect of granise-
tron, a compound similar to ondansetron. Four of 5 patients 
showed a remarkable improvement that reversed after ces-
sation of the drug.21 Of course, such an open study is prone 
to observer bias, and a placebo effect cannot be excluded. 
However, in earlier studies in chronic fatigue syndrome 
performed by us34,35 and others,36 placebo effects were min-
imal. Besides pharmacologic and neuroendocrine studies 
implicating an increased 5-HT neurotransmission, positron 
emission tomography (PET) supports the hypothesis of an 
increased serotonergic state in chronic fatigue syndrome. 
Cleare et al37 found a widespread reduction in the num-
ber or affinity of 5-HT1A receptors, and the results of this 
study may be compatible with the neuroendocrine studies. 
A prolonged increased 5-HT state might result in a chronic 
5-HT down-regulation and, consequently, reduced 5-HT 
binding potential.37
On the basis of all of these previous findings, the ques-
tion arises why our trial met with negative results. We have 
scrutinized our study regarding potential confounding 
factors, but could not identify any. The groups were well 
matched, and only well-diagnosed patients with chronic fa-
tigue syndrome fulfilling the CDC criteria were included. 
Furthermore, we excluded patients with current psychiatric 
comorbidity. In this clinical study, we investigated the ef-
fect of serotonin receptor antagonism with ondansetron. We 
included patients from the outpatient clinic of the depart-
ment of general internal medicine and patients who were 
referred by the general practitioner to the Expert Center 
Chronic Fatigue for treatment. Patients with chronic fatigue 
syndrome who were taking serotonergic medication were 
excluded from participating in the study.
We also chose to exclude patients with current psychiat-
ric comorbidity. Methodological differences and definition 
difficulties in the literature have produced conflicting re-
sults concerning the prevalence of psychiatric disorders 
in chronic fatigue syndrome and the impact of psychiatric 
disorders on the prognosis of chronic fatigue syndrome.38 
Furthermore, evidence suggests an important role for the 
neurotransmitter serotonin in psychiatric disorders, such as 
in depression39,40 and in the pathophysiology and treatment 
of anxiety and panic attacks.41,42 In this way, we reduced 
the chance the results will be biased by current Axis I psy-
chiatric disorders. To our knowledge, ondansetron has no 
significant role in the treatment of depression, anxiety dis-
orders, or obsessive-compulsive disorders.43 Therefore, we 
do not believe that excluding patients with current psychi-
atric comorbidity has reduced the likelihood of achieving 
response to ondansetron.
In our open-label study, we used granisetron, at that time 
marketed by SmithKline Beecham. When we were design-
ing the present study, SmithKline Beecham merged with 
GlaxoWellcome and sold granisetron to Roche. Although 
Table 2. Scores on Outcome Measures and ANCOVA Results 








Outcome Measure Mean SD Mean SD F P
Primary outcome measures
CIS-fatigue 0.116 .73
Pretreatment 49.4 6.3 50.0 4.7
Posttreatment 44.0 11.1 45.4 11.5
SIP-8 1.077 .30
Pretreatment 1,375 470.0 1,359 593.4
Posttreatment 1,063 525.5 1,172 694.6
Secondary outcome measures
Actometer 0.773 .38
Pretreatment 54.1 16.5 58.4 16.6
Posttreatment 55.0 15.5 60.6 17.9
DOF 0.015 .90
Pretreatment 8.5 2.0 8.4 2.0
Posttreatment 7.9 2.4 7.8 2.8
Abbreviations: ANCOVA = analysis of covariance,  
CIS-fatigue = Checklist Individual Strength fatigue severity subscale, 
DOF = daily observed fatigue, SIP-8 = Sickness Impact Profile-8.
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this is a fully investigator-driven study, we were not able to 
obtain granisetron and placebo for the randomized con-
trolled trial. Thus, we had to redesign the study and use 
ondansetron. Granisetron and ondansetron are both selec-
tive 5-HT3 receptor antagonists.
To our knowledge, no differences in efficacy and side 
effects are described between the different 5-HT3 receptor 
antagonists. Given the similarities between the 2 drugs, we 
feel it is highly unlikely that the switch to ondansetron ex-
plains our negative results.
We did not monitor patient compliance on a daily basis. 
During the trial, patients had an appointment by telephone 
or at the outpatient clinic every 2 weeks. During these ap-
pointments, we assessed whether patients experienced side 
effects and whether the trial medication was taken as direct-
ed. Although we have not rigorously checked compliance, 
we do not believe that lack of adherence can explain the 
negative findings.
We did not assess the baseline serotonin status of the 
patients with chronic fatigue syndrome. As mentioned pre-
viously, results from neuroendocrine challenge studies have 
suggested increased central 5-HT function in patients with 
chronic fatigue syndrome. Several different 5-HT agonists 
have been used to assess 5-HT function in chronic fatigue 
syndrome. Studies with buspirone10 and d-fenfluramine11,12 
showed an enhanced prolactin response in patients with 
chronic fatigue syndrome compared to healthy controls 
and depressed subjects. Others showed a normal 5-HT 
activity.44,45 Appropriateness of matching and selection of 
patients with chronic fatigue syndrome with heterogeneous 
psychiatric history could partly contribute to the inconsis-
tent findings in the 5-HT challenge studies.5 One possible 
explanation is heterogeneity of the central serotonin bio-
synthetic status within the patients with chronic fatigue 
syndrome, measured as the ratio of serum tryptophan to 
the sum of its competing large neutral amino acids.46 In our 
study, we do not know if the patients had a high serotonin 
status. If the patients in the ondansetron treatment group 
had a normal serotonin status, one could hypothesize that 
receptor antagonism could not be effective in these patients. 
However, we did not see any differences in the pattern of 
response between the placebo and the ondansetron group. 
For example, in both treatment groups, an equal number of 
8 patients showed an improvement of more than 10 points 
in the CIS-fatigue severity.
In our clinical trial, we could detect changes over time 
in both groups. We have assessed the effects with validated 
instruments designed to assess different dimensions of 
chronic fatigue syndrome as well as treatment effects. In 
our trials on cognitive behavior therapy,4,26 those instru-
ments were robust and reliable to show improvement at the 
group level as well as at the level of the individual patient. 
The negative findings in this randomized controlled trial 
cannot be explained by a power problem. In our opinion, it 
is very unlikely that a larger trial would detect a clinically 
relevant effect. The lack of significant differences on self-
report outcome measures and physical activity strengthens 
our overall findings.
In conclusion, this randomized, placebo-controlled 
trial did not demonstrate any benefit in chronic fatigue 
syndrome–related outcome measures. Thus, the findings of 
this clinical trial do not support the use of 5-HT3 antagonism 
in treating chronic fatigue syndrome–related symptoms.
Drug names: buspirone (BuSpar and others), granisetron  
(Sancuso, Kytril, and others), ondansetron (Zofran and others).
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